Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Cybin

Cybin-Announces-Dosing-of-First-Patients-in-Phase-1-2a-Clinical-Trial-of-CYB003-Psilocybin-Analog-for-Depression Psychedeic-Chronicle-Logo-White
Psychedelic News

Cybin Announces Dosing of First Patients in Phase 1/2a Clinical Trial of CYB003 Psilocybin Analog for Depression

Psychedelic biopharmaceutical company Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announced today the dosing of the first two patients in the company’s Phase

August 30, 2022

Recent Posts

  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial
  • Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio
  • Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression

Recent Comments

No comments to show.

Popular

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS